These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36229853)

  • 1. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
    Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
    Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Huang J; Zhang D; Bai Y; Yang P; Xing L; Yu J
    J Cancer; 2020; 11(12):3685-3692. PubMed ID: 32284765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A
    Dziedzic K; Węgrzyn P; Gałęzowski M; Bońkowska M; Grycuk K; Satała G; Wiatrowska K; Wiklik K; Brzózka K; Nowak M
    Int Immunopharmacol; 2021 Jul; 96():107645. PubMed ID: 33894488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Combination Strategies for the A
    Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
    Front Immunol; 2021; 12():617316. PubMed ID: 33737925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
    Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
    Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway.
    Masjedi A; Hassannia H; Atyabi F; Rastegari A; Hojjat-Farsangi M; Namdar A; Soleimanpour H; Azizi G; Nikkhoo A; Ghalamfarsa G; Mirshafiey A; Jadidi-Niaragh F
    Int J Biol Macromol; 2019 Jul; 133():436-445. PubMed ID: 30936011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
    Sun C; Wang B; Hao S
    Front Immunol; 2022; 13():837230. PubMed ID: 35386701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
    Fallah-Mehrjardi K; Mirzaei HR; Masoumi E; Jafarzadeh L; Rostamian H; Khakpoor-Koosheh M; Alishah K; Noorbakhsh F; Hadjati J
    Immunol Lett; 2020 Jul; 223():44-52. PubMed ID: 32289340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A2a adenosine receptor agonist improves endoplasmic reticulum stress in MIN6 cell line through protein kinase A/ protein kinase B/ Cyclic adenosine monophosphate response element-binding protein/ and Growth Arrest And DNA-Damage-Inducible 34/ eukaryotic Initiation Factor 2α pathways.
    Arasi FP; Shahrestanaki MK; Aghaei M
    J Cell Physiol; 2019 Jul; 234(7):10500-10511. PubMed ID: 30417358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
    Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
    Seitz L; Jin L; Leleti M; Ashok D; Jeffrey J; Rieger A; Tiessen RG; Arold G; Tan JBL; Powers JP; Walters MJ; Karakunnel J
    Invest New Drugs; 2019 Aug; 37(4):711-721. PubMed ID: 30569245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells.
    Bshesh K; Zhao B; Spight D; Biaggioni I; Feokistov I; Denenberg A; Wong HR; Shanley TP
    J Leukoc Biol; 2002 Nov; 72(5):1027-36. PubMed ID: 12429726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.
    Ohta A; Madasu M; Subramanian M; Kini R; Jones G; Choukèr A; Ohta A; Sitkovsky M
    Int Immunol; 2014 Feb; 26(2):83-91. PubMed ID: 24150242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADENOSINE INFLUENCES FOXP3 EXPRESSION OF T REGS VIA THE A2AR/CREB PATHWAY IN A MOUSE MODEL OF SEPSIS.
    Zhang T; Fu W; Liu D; He Y; Wang J; Ma T
    Shock; 2024 Jun; 61(6):924-933. PubMed ID: 38010286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.